Short answer
Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Fulcrum terminated its worldwide exclusive Diamond-Blackfan anemia license with CAMP4, effective under agreement terms.
Fulcrum Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Fulcrum terminated its worldwide exclusive Diamond-Blackfan anemia license with CAMP4, effective under agreement terms
- Termination removes potential obligations for up to $35.0 million in development and regulatory milestones
- Termination also eliminates up to $35.0 million in sales milestones and future royalties
- Decision ends Fulcrum’s rights to CAMP4 compounds, patents, know-how and related sublicensing rights
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results announced for quarter ended March 31, 2026
- Full financial results and management commentary available in Exhibit 99.1
- Filing under Item 2.02 signals earnings information relevant to valuation and investor expectations
Item 5.02 · Departure/Election of Directors or Officers
- Josh Lehrer appointed independent Class III director through 2028 annual meeting
- Science & Technology Committee assignment adds board-level scientific expertise
- One-time option grant for 64,000 shares at $8.08 exercise price
- CFO Alan Musso retiring; successor search underway, with consulting support through February 2027
- Extended option exercise period and transition benefits increase departure-related compensation obligations
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 cash, equivalents and marketable securities of $333.3M support operating runway into 2029
- Pociredir data showed rapid HbF induction, improved hemolysis and anemia markers, and encouraging VOC reduction trends
- FDA feedback expected in Q2 2026 ahead of a potential registration-enabling trial planned for H2 2026
- Q1 net loss increased to $18.9M from $17.7M, while operating expenses rose to $22.2M
- CFO Alan Musso plans to retire later in 2026, creating a leadership transition during pivotal development planning
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulcrum Therapeutics, Inc. 8-K filings
Get the next FULC 8-K as it lands
Follow FULC for push alerts, or ask the research agent what this filing means.